Biotechnology and pharmaceuticals in Hamburg and Schleswig-Holstein - growth and variety - knowledge and planning

In Life Science Nord, the field of biotechnology is characterized by a wide range of companies. Around 80 companies with a total of approximately 8,200 employees research and work in Hamburg and Schleswig-Holstein in biotechnological fields for medical and industrial application. In addition, there are around 70 companies in the pharmaceutical industry. In both states, the focus is on red (medical) biotechnology, chiefly the fields of pharmaceuticals and medicine. The core competencies in biotech/pharmaceuticals are in the areas of agent research, molecular diagnostics and platform technologies, including nanotechnologies and marine biotechnology.

The pharmaceuticals industry is closely tied to life sciences. Major medical producers and large-scale trading companies operate in both, Hamburg and Schleswig-Holstein.  Large international pharmaceutical companies, such as GlaxoSmithKline, AstraZeneca and Ferring maintain research, production and sales locations in the Northern Germany region and develop innovative, biopharmaceutical products here. The core areas of the Northern German medical producers include neurology, oncology, allergology, pain therapy and dermatology.

Evotec AG has positioned itself as the provider of a development platform for the screening of new agents. As an excellent project for the North Germany Life Science location, the European ScreeningPort (ESP) agent research center was launched in 2007. The ESP supplies an industrially organized platform to European research institutes, to allow more efficient and systematic identification of viable agents for future medicines and to promote their development. Both Evotec AG and the City of Hamburg are shareholders in the company.


⇒ Industrial cell technology

Strategic network for industrial cell technology

The future development of therapeutic agents, cell-based therapy concepts or the bioproduction of complex substances requires new platform technologies. Here, three-dimensional cell cultures, made up of multiple cell types, appropriate device technologies and new materials all play key roles. Work on an industrial scale as well as product development are possible. This "industrial cell technology" is used, for example, in biomedical research, medical technology, in the food industry and in marine biotechnology.

The Germany Society for Industrial Cell Technology was founded in September 2011 in co-operation with the Norgenta North German Life Science Agency and under the leadership of the Fraunhofer Research Institution for Marine Biotechnology (EMB), in order to promote the development of industrial cell technology.

Please refer to the brief information or the website for further information.


⇒ Marine Biotechnology

Submariner - Sustainable Uses of Baltic Marine Resources

As part of the EU Baltic Sea Region Program (formerly INTERREG-IV-B), a total of 19 partners from eight countries of the Baltic Sea region have joined together to work on new concepts and visions for sustainable use of the enormous resources of the Baltic Sea in various areas.

Please refer to the brief information or the website for further information.


CSA Marine Biotech: ERA-NET Preparatory Action in the Marine Biotechnology

In the "CSA Marine Biotech" project, 11 partners from 9 countries have joined together to take the first concrete steps towards a coordinated European research area in the field of marine biotechnology.

The future ERA-NET marine biotechnology is intended to counteract the fragmentation of the European research area. On the German side, Norgenta is involved in this FP7 project through the mobilization and inclusion of the relevant European players.

You can find further information about the project on the website.


Marine Fungi – Natural Products from marine fungi for the treatment of cancer

The EU research project, launched in May 2011 under the leadership of the GEOMAR Helmholtz Centre for Oceanic Research in Kiel, is researching the sustainable collection of medical agents from marine organisms. The 11 partners have focused particularly on marine fungi, which, in the past, showed themselves as a potent source for biotechnological applications.

Please refer to the brief information or the website for detailed information.


The excellence cluster "Ocean of the Future"

Experts from many kinds of disciplines bundle their knowledge in the excellence cluster: For example, lawyers and geoscientists answer questions on how and by whom the resources on the seabed may be used. Climate researchers and economists work on the conditions under which CO2 storage on the sea bed is sensible. Marine researchers, doctors, mathematicians, chemists, engineers and social scientists have dedicated themselves to answer further questions.

Here you get more information about the excellence cluster


⇒ Drug Development / Research

NEU² - North German consortium for the development of new therapies against neurological illnesses

Multiple winner of the BMBF BioPharma competition: The objective of the Neu2 consortium, which is focused on multiple sclerosis, is to accompany therapeutic and diagnostic approaches to the treatment of multiple sclerosis patients from initial research through to market launch.

You can find detailed information about the projects and the consortium partners on the website


European Center for the research of new agents in Hamburg - European ScreeningPort GmbH

The European ScreeningPort is a highly modern service center for research into new medical agents. As a public-private partnership between the Free Hanseatic City of Hamburg and Evotec AG, the company serves as a link between academic agent research and the pharmaceuticals industry.

You can find detailed information on the website


The excellent cluster "Inflammation at Interfaces"

Chronic inflammations of the human body is the central challenge facing medicine in the 21st  century. The excellence cluster bundles the competences of around 150 highly-specialized researchers and doctors. The scientists use an infrastructure, rated "Excellent" in an international comparison, provided by the Universities of Kiel and Lübeck, the Leibniz Research Center for Medicine and Bioscience in Borstel and the Max-Planck-Institute for Evolutionary Biology in Plön.

You can find more detailed information on the website at


Center for Applied Nanotechnology

CAN GmbH offers chartered research and development services in the field of nanotechnology for companies and research institutions, and is involved in national and international research programs.

You can find further information on the research and services of the company on the CAN website:


"Initiative Industrielle Biotechnologie Nord" - IBN

Experts from the five northern German federal states have joined together into the "Initiative Industrielle Biotechnologie Nord (IBN)" with the aim of strengthening research and development in industrial biotechnology in northern Germany.

To find out more about the network, click here.